When does Alecensa (alectinib) exclusivity end?
Alecensa (alectinib) has multiple layers of time protection in different jurisdictions (patents, regulatory exclusivity, and related legal protections). That means there isn’t a single universal “expiry date” that applies everywhere.
What exact kind of “expiry date” do you mean?
People asking for an Alecensa “expiry date” usually mean one of these:
- Patent expiry (the date a specific patent(s) protecting the drug ends in a country)
- Regulatory exclusivity expiry (a marketing-protection period after approval)
- Biosimilar/generic entry timing (often driven by the above, plus local market-authorization rules)
Which one you need determines the date and source.
Which country’s date are you looking for (US, EU, UK, Canada, etc.)?
The date can differ by country because patents and exclusivity periods are filed and granted separately in each region. If you tell me the country (for example, US vs EU/UK), I can narrow to the relevant protection windows.
Is there a single “patent expiry” month/year for all of Alecensa?
No. Alecensa’s protection is typically spread across several patents with different filing and grant dates, plus possible additional protections (like patent-term adjustments or extensions, depending on the jurisdiction). So you usually see multiple “expiry” dates rather than one.
What should you provide so I can give the correct expiry timeline?
Reply with:
1) Country/region (US, EU, UK, Canada, etc.)
2) Whether you mean patent expiry or regulatory exclusivity
3) (If you have it) the patent number or the program you’re tracking
With those, I can give the specific Alecensa expiry date(s) that match your intent.